These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36588113)

  • 1. LIGHTSITE II Randomized Multicenter Trial: Evaluation of Multiwavelength Photobiomodulation in Non-exudative Age-Related Macular Degeneration.
    Burton B; Parodi MB; Jürgens I; Zanlonghi X; Hornan D; Roider J; Lorenz K; Munk MR; Croissant CL; Tedford SE; Walker M; Ruckert R; Tedford CE
    Ophthalmol Ther; 2023 Apr; 12(2):953-968. PubMed ID: 36588113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System.
    Boyer D; Hu A; Warrow D; Xavier S; Gonzalez V; Lad E; Rosen RB; Do D; Schneiderman T; Ho A; Munk MR; Jaffe G; Tedford SE; Croissant CL; Walker M; Rückert R; Tedford CE
    Retina; 2024 Mar; 44(3):487-497. PubMed ID: 37972955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photobiomodulation for non-exudative age-related macular degeneration.
    Henein C; Steel DH
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013029. PubMed ID: 34097768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Invasive Treatment of Early Diabetic Macular Edema by Multiwavelength Photobiomodulation with the Valeda Light Delivery System.
    Kaymak H; Munk MR; Tedford SE; Croissant CL; Tedford CE; Ruckert R; Schwahn H
    Clin Ophthalmol; 2023; 17():3549-3559. PubMed ID: 38026594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.
    Markowitz SN; Devenyi RG; Munk MR; Croissant CL; Tedford SE; Rückert R; Walker MG; Patino BE; Chen L; Nido M; Tedford CE
    Retina; 2020 Aug; 40(8):1471-1482. PubMed ID: 31404033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration.
    Borrelli E; Coco G; Pellegrini M; Mura M; Ciarmatori N; Scorcia V; Carnevali A; Lucisano A; Borselli M; Rossi C; Reibaldi M; Ricardi F; Vagge A; Nicolò M; Forte P; Cartabellotta A; Hasanreisoğlu M; Kesim C; Demirel S; Yanık Ö; Bernabei F; Rothschild PR; Farrant S; Giannaccare G
    Ophthalmol Ther; 2024 Nov; 13(11):2855-2868. PubMed ID: 39271642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shedding Light on Photobiomodulation Therapy for Age-Related Macular Degeneration: A Narrative Review.
    Fantaguzzi F; Tombolini B; Servillo A; Zucchiatti I; Sacconi R; Bandello F; Querques G
    Ophthalmol Ther; 2023 Dec; 12(6):2903-2915. PubMed ID: 37768527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter to the Editor Regarding "LIGHTSITE II Randomized Multicenter Trial: Evaluation of Multiwavelength Photobiomodulation in Non-exudative Age-Related Macular Degeneration".
    Grisanti S; Bartz-Schmidt KU; Heimann H; Lommatzsch A; Walter P; Ach T
    Ophthalmol Ther; 2024 Apr; 13(4):1051-1053. PubMed ID: 38319554
    [No Abstract]   [Full Text] [Related]  

  • 9. Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration.
    Merry GF; Munk MR; Dotson RS; Walker MG; Devenyi RG
    Acta Ophthalmol; 2017 Jun; 95(4):e270-e277. PubMed ID: 27989012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHOTOBIOMODULATION THERAPY FOR LARGE SOFT DRUSEN AND DRUSENOID PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION: A Single-Center Prospective Pilot Study.
    Benlahbib M; Cohen SY; Torrell N; Colantuono D; Crincoli E; Amoroso F; Semoun O; Jung C; Souied EH
    Retina; 2023 Aug; 43(8):1246-1254. PubMed ID: 37027819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment - Case Report.
    Sachdev A
    Ophthalmol Ther; 2024 Jul; 13(7):2055-2060. PubMed ID: 38758517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement inhibitors for age-related macular degeneration.
    Tzoumas N; Riding G; Williams MA; Steel DH
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009300. PubMed ID: 37314061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical studies of photobiomodulation therapy for macular oedema.
    Shen W; Teo KYC; Wood JPM; Vaze A; Chidlow G; Ao J; Lee SR; Yam MX; Cornish EE; Fraser-Bell S; Casson RJ; Gillies MC
    Diabetologia; 2020 Sep; 63(9):1900-1915. PubMed ID: 32661752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photobiomodulation efficacy in age-related macular degeneration: a systematic review and meta-analysis of randomized clinical trials.
    Rassi TNO; Barbosa LM; Pereira S; Novais EA; Penha F; Roisman L; Maia M
    Int J Retina Vitreous; 2024 Aug; 10(1):54. PubMed ID: 39148091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Response to: Letter to the Editor Regarding "LIGHTSITE II Randomized Multicenter Trial: Evaluation of Multiwavelength Photobiomodulation in Non-exudative Age-Related Macular Degeneration".
    Burton B; Munk MR; Tedford SE; Croissant CL; Rückert R; Tedford CE
    Ophthalmol Ther; 2024 Apr; 13(4):1055-1060. PubMed ID: 38319553
    [No Abstract]   [Full Text] [Related]  

  • 16. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
    Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
    Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
    Chan CK; Lalezary M; Abraham P; Elman M; Beaulieu WT; Lin SG; Khurana RN; Bansal AS; Wieland MR; Palmer JD; Chang LK; Lujan BJ; Yiu G;
    Ophthalmol Retina; 2022 Jun; 6(6):484-494. PubMed ID: 35121216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Lukacs R; Schneider M; Nagy ZZ; Sandor GL; Kaan K; Asztalos A; Enyedi L; Pek G; Barcsay G; Szabo A; Borbandy A; Kovacs I; Resch MD; Papp A
    BMC Ophthalmol; 2023 Mar; 23(1):110. PubMed ID: 36932356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial.
    Boyer DS; Gonzalez VH; Kunimoto DY; Maturi RK; Roe RH; Singer MA; Xavier S; Kornfield JA; Kuppermann BD; Quiroz-Mercado H; Aubel J; Karageozian HL; Park JY; Karageozian VH; Karageozian L; Sarayba MA; Kaiser PK
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):327-335. PubMed ID: 34185587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial.
    Nittala MG; Metlapally R; Ip M; Chakravarthy U; Holz FG; Staurenghi G; Waheed N; Velaga SB; Lindenberg S; Karamat A; Koester J; Ribeiro R; Sadda S
    JAMA Ophthalmol; 2022 Mar; 140(3):243-249. PubMed ID: 35113137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.